A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis
Clinical trial NCT02149706 · UNKNOWN
Trial details
- NCT number
- NCT02149706
- Sponsor
- Immune Response BioPharma, Inc.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-03-09
- Primary completion
- 2022-03-09
- Enrollment
- 150
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.